COMMUNIQUÉS West-GlobeNewswire

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
23/09/2025
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc. , an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, [...]
Labviva Kicks Off Smart Lab of the Future Tour
23/09/2025
Life sciences procurement leader showcases AI-driven supply chain innovation at global events BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Labviva , the leading AI-powered procurement platform for life sciences, today [...]
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Pratteln, Switzerland, September 23, [...]
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 BST. Details are at the end of this news release Pratteln, Switzerland, September 23, [...]
Addex Appoints Bank of New York Mellon as Depositary Bank
23/09/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
23/09/2025
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expression Myotonic [...]
Communiqué de presse : La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1
23/09/2025
La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1 Admission obtenue pour la thérapie génique AAV unique [...]
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR Highlights: Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global rollout Demand for AGAMREE [...]
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
23/09/2025
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]

Pages